Role of beta-(1→3)(1→6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures.
Anticancer
Beta-glucan
Breast cancer
NK cell
Spheroids
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
received:
25
08
2023
accepted:
07
02
2024
medline:
18
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
epublish
Résumé
Beta-(1,3)(1,6)-D-glucan is a complex polysaccharide, which is found in the cell wall of various fungi, yeasts, bacteria, algae, barley, and oats and has immunomodulatory, anticancer and antiviral effects. In the present study, we investigated the effect of beta-(1,3)(1,6)-D-glucan derived from yeast on the proliferation of primary NK cells and breast cancer cell lines in 2D and 3D models, and on the cytotoxicity of primary NK cells against breast cancer cell lines in 2D and 3D models. In this study, we investigated the effects of different concentrations of yeast-derived beta-(1→3)(1→6)-D-glucan on the proliferation and cytotoxicity of human NK cells and breast cancer cell lines in 2D and 3D models using the XTT cell proliferation assay and the CellTiter-Glo® 2.0 assay to determine the cytotoxicity of human NK cells on breast cancer cell lines in 2D and 3D models. We found that the co-incubation of NK cells with beta-glucan in the absence of IL2 at 48 h significantly increased the proliferation of NK cells, whereas the co-incubation of NK cells with beta-glucan in the presence of IL2 (70 U/ml) increased the proliferation of NK cells but not significantly. Moreover, beta-glucan significantly inhibited the proliferation of breast cancer cell lines in 2D model and induced a weak, non-significant growth inhibitory effect on breast cancer multicellular tumor spheroids (3D). In addition, the cytotoxicity of NK cells against breast cancer cell lines was examined in 2D and 3D models, and beta-glucan significantly increased the cytotoxicity of NK cells against MCF-7 (in 2D). Yeast derived beta-(1,3)(1,6)-D-glucan could contribute to the treatment of cancer by enhancing NK cell immune response as well as contributing to inhibition of breast cancer cell growth.
Sections du résumé
BACKGROUND
BACKGROUND
Beta-(1,3)(1,6)-D-glucan is a complex polysaccharide, which is found in the cell wall of various fungi, yeasts, bacteria, algae, barley, and oats and has immunomodulatory, anticancer and antiviral effects. In the present study, we investigated the effect of beta-(1,3)(1,6)-D-glucan derived from yeast on the proliferation of primary NK cells and breast cancer cell lines in 2D and 3D models, and on the cytotoxicity of primary NK cells against breast cancer cell lines in 2D and 3D models.
METHODS
METHODS
In this study, we investigated the effects of different concentrations of yeast-derived beta-(1→3)(1→6)-D-glucan on the proliferation and cytotoxicity of human NK cells and breast cancer cell lines in 2D and 3D models using the XTT cell proliferation assay and the CellTiter-Glo® 2.0 assay to determine the cytotoxicity of human NK cells on breast cancer cell lines in 2D and 3D models.
RESULTS
RESULTS
We found that the co-incubation of NK cells with beta-glucan in the absence of IL2 at 48 h significantly increased the proliferation of NK cells, whereas the co-incubation of NK cells with beta-glucan in the presence of IL2 (70 U/ml) increased the proliferation of NK cells but not significantly. Moreover, beta-glucan significantly inhibited the proliferation of breast cancer cell lines in 2D model and induced a weak, non-significant growth inhibitory effect on breast cancer multicellular tumor spheroids (3D). In addition, the cytotoxicity of NK cells against breast cancer cell lines was examined in 2D and 3D models, and beta-glucan significantly increased the cytotoxicity of NK cells against MCF-7 (in 2D).
CONCLUSIONS
CONCLUSIONS
Yeast derived beta-(1,3)(1,6)-D-glucan could contribute to the treatment of cancer by enhancing NK cell immune response as well as contributing to inhibition of breast cancer cell growth.
Identifiants
pubmed: 38486205
doi: 10.1186/s12885-024-11979-3
pii: 10.1186/s12885-024-11979-3
pmc: PMC10938759
doi:
Substances chimiques
Glucans
0
Interleukin-2
0
beta-Glucans
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
339Informations de copyright
© 2024. The Author(s).
Références
Breast Cancer Res Treat. 2004 Feb;83(3):249-89
pubmed: 14758095
Oncol Rep. 2015 Apr;33(4):1837-43
pubmed: 25634491
J Clin Invest. 2006 Apr;116(4):916-28
pubmed: 16543948
Mutat Res. 2008 Mar-Apr;658(3):154-61
pubmed: 17827055
Eur J Immunol. 2005 May;35(5):1539-47
pubmed: 15816015
Front Immunol. 2020 Apr 22;11:658
pubmed: 32391005
Phytother Res. 2014 Feb;28(2):159-66
pubmed: 23494974
Am J Clin Nutr. 2006 Mar;83(3):601-5
pubmed: 16522906
Lancet Oncol. 2021 Jan;22(1):e18-e28
pubmed: 33387500
Int J Mol Sci. 2019 Jul 24;20(15):
pubmed: 31344853
Cancer. 1980 May 1;45(9):2404-13
pubmed: 6445777
J Toxicol Environ Health A. 2020 Feb 16;83(4):135-152
pubmed: 32114934
J Biol Chem. 2000 Jun 30;275(26):20157-67
pubmed: 10779524
Ann Transl Med. 2015 Feb;3(2):22
pubmed: 25738142
J Hematol Oncol. 2009 Jun 10;2:25
pubmed: 19515245
Oncotarget. 2016 Jul 19;7(29):45745-45756
pubmed: 27304190
Clin Breast Cancer. 2021 Aug;21(4):e377-e387
pubmed: 33451964
Front Cell Dev Biol. 2021 Mar 11;9:647736
pubmed: 33777954
Vaccine. 2018 Aug 23;36(35):5235-5244
pubmed: 30049632
Biosci Rep. 2020 Dec 23;40(12):
pubmed: 33245358
Cancer Med. 2016 Apr;5(4):703-10
pubmed: 26763588
Appl Physiol Nutr Metab. 2010 Dec;35(6):755-62
pubmed: 21164546
Eur J Cancer (1965). 1979 May;15(5):659-70
pubmed: 228940
Nat Rev Cancer. 2007 Sep;7(9):659-72
pubmed: 17721431
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Mol Nutr Food Res. 2021 Jan;65(1):e1901071
pubmed: 32223047
Carbohydr Res. 2016 Apr 7;424:30-41
pubmed: 26974354
Carbohydr Polym. 2013 Jan 30;92(1):792-809
pubmed: 23218369
Physiology (Bethesda). 2017 Jul;32(4):266-277
pubmed: 28615311
Front Bioeng Biotechnol. 2020 Sep 04;8:1040
pubmed: 33015012
Assay Drug Dev Technol. 2014 May;12(4):207-18
pubmed: 24831787
Med Mycol. 2017 Jul 1;55(5):573-578
pubmed: 28873980
Anticancer Res. 2018 Mar;38(3):1327-1333
pubmed: 29491056
Carbohydr Polym. 2014 Jan 30;101:819-27
pubmed: 24299844
J Natl Cancer Inst. 1973 Nov;51(5):1409-16
pubmed: 4357757
PLoS One. 2013;8(3):e59689
pubmed: 23555746
BMC Complement Altern Med. 2011 Jul 25;11:58
pubmed: 21787425
Sci Rep. 2017 Mar 23;7:44990
pubmed: 28332554
J Immunol. 2002 Oct 1;169(7):3876-82
pubmed: 12244185
Int J Biol Sci. 2017 Nov 1;13(11):1387-1397
pubmed: 29209143
Adv Drug Deliv Rev. 2018 Jul;132:235-251
pubmed: 29935988
J Biol Chem. 2009 Mar 13;284(11):7038-46
pubmed: 19136564
Mater Today (Kidlington). 2015 Dec;18(10):539-553
pubmed: 28458612
Complement. 1987;4(2):75-86
pubmed: 3040333
Front Biosci (Schol Ed). 2020 Mar 1;12(1):137-160
pubmed: 32114452
Pharmaceutics. 2020 Dec 06;12(12):
pubmed: 33291351
Evid Based Complement Alternat Med. 2018 Feb 26;2018:8324696
pubmed: 29681985
J Leukoc Biol. 2002 Jul;72(1):140-6
pubmed: 12101273
Clin Infect Dis. 2020 Jan 2;70(2):232-241
pubmed: 30877304
Arch Pathol Lab Med. 1991 Feb;115(2):141-4
pubmed: 1992979
J Infect. 2018 Sep;77(3):235-241
pubmed: 29972764
Breast Cancer Res. 2011 Aug 12;13(4):215
pubmed: 21884641
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643230
Endocr Metab Immune Disord Drug Targets. 2009 Mar;9(1):67-75
pubmed: 19275682
Cancers (Basel). 2020 Jan 08;12(1):
pubmed: 31936360
Cell Adh Migr. 2012 Nov-Dec;6(6):547-53
pubmed: 23257828
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
J Biol Chem. 1998 Aug 21;273(34):22014-20
pubmed: 9705343
Cancer Res. 2002 Sep 1;62(17):4977-84
pubmed: 12208749
Trends Biotechnol. 2015 Nov;33(11):667-678
pubmed: 26603572
J Toxicol Environ Health A. 2019;82(9):537-549
pubmed: 31258008
Int J Oncol. 2013 Aug;43(2):357-64
pubmed: 23739801
Anticancer Agents Med Chem. 2013 Jun;13(5):699-708
pubmed: 23140352
Crit Rev Food Sci Nutr. 2019;59(6):992-1007
pubmed: 30795687
Adv Drug Deliv Rev. 2014 Dec 15;79-80:214-21
pubmed: 24816064
Front Cell Dev Biol. 2019 Aug 13;7:165
pubmed: 31457012
Mol Biol Rep. 2020 May;47(5):3653-3661
pubmed: 32323263
Clin Nutr. 2021 May;40(5):3104-3113
pubmed: 33309412
Anticancer Res. 2020 Jun;40(6):3139-3145
pubmed: 32487608
In Vitro. 1978 Nov;14(11):911-5
pubmed: 730202
Oncotarget. 2017 Sep 30;8(49):86693-86709
pubmed: 29156828
J Ovarian Res. 2020 Mar 5;13(1):24
pubmed: 32138756
Front Immunol. 2017 Jul 07;8:791
pubmed: 28736555
J Cancer Res Clin Oncol. 2015 May;141(5):951-9
pubmed: 25773123
Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):656-61
pubmed: 20842027